Chapter 31. Signaling Pathways and Rationale for Molecular Therapies in Hepatocellular Carcinoma

  1. Pierre-Alain Clavien MD, Phd, FACS, FRCS Professor Chairman and
  2. Stefan Breitenstein MD
  1. Augusto Villanueva MD1,
  2. Clara Alsinet PhD1 and
  3. Josep M. Llovet MD Associate Professor of Medicine Professor of Research2,3

Published Online: 9 DEC 2009

DOI: 10.1002/9781444317053.ch31

Malignant Liver Tumors: Current and Emerging Therapies, Third Edition

Malignant Liver Tumors: Current and Emerging Therapies, Third Edition

How to Cite

Villanueva, A., Alsinet, C. and Llovet, J. M. (2009) Signaling Pathways and Rationale for Molecular Therapies in Hepatocellular Carcinoma, in Malignant Liver Tumors: Current and Emerging Therapies, Third Edition (eds P.-A. Clavien and S. Breitenstein), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444317053.ch31

Editor Information

  1. Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland

Author Information

  1. 1

    Barcelona-Clinic-Liver-Cancer (BCLC) Group, Institut d' Investigacions Biomèdiques August Pi, i Sunyer (IDIBAPS), Centro de Investigaciones Biomédicas en Red (CIBEREHD), Liver Unit, Hospital Clínic, Barcelona, Spain

  2. 2

    Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York, USA

  3. 3

    HCC Translational Research Lab, ICREA, Barcelona-Clinic-Liver-Cancer (BCLC) Group, Institut d' Investigacions Biomèdiques August Pi, i Sunyer (IDIBAPS), Centro de Investigaciones Biomédicas en Red (CIBEREHD), Liver Unit, Hospital Clínic, Barcelona, Spain

Publication History

  1. Published Online: 9 DEC 2009
  2. Published Print: 12 JAN 2010

ISBN Information

Print ISBN: 9781405179768

Online ISBN: 9781444317053

SEARCH

Keywords:

  • Hepatocellular carcinoma (HCC);
  • BCLC (Barcelona Clinic Liver Cancer);
  • comparative genomic hybridization (CGH);
  • epidermal growth factor receptor (EGFR);
  • Hepatocyte growth factor (HGF);
  • European Medicines Agency (EMEA);
  • tyrosine kinase receptors (TKRs);
  • transarterial chemoembolization [TACE]

Summary

This chapter contains sections titled:

  • Introduction

  • Molecular pathogenesis of hepatocellular carcinoma

  • Molecular-t argeted therapies: a n ovel approach in the management of hepatocellular carcinoma

  • Future research

  • Self-assessment questions

  • References

  • Self-assessment answers